Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1994-4-12
|
| pubmed:abstractText |
A second generation hepatitis C virus recombinant immunoblot assay (RIBA) was used to screen stored perioperative serum from 641 renal allograft recipients. One hundred and nine (17%) were anti-HCV positive at the time of transplant. RIBA positivity was found to be an independent predictor of post-transplant liver disease in a logistic regression model (P < 0.05). Moreover, RIBA positive patients were at greater risk for infectious events (P = 0.03) and rejection episodes (P = 0.002). The cumulative dose of antilymphoblast globulin administered as induction therapy was an independent predictor of post-transplant liver disease in a dose response relationship. Qualitative PCR showed that 74% of the perioperative RIBA positive patients had detectable HCV RNA in a current serum sample. Further, quantitative HCV RNA analysis with a competitive template PCR and HCV strain identification by restriction fragment length polymorphism demonstrated a large range of HCV RNA copies/ml of serum and three different HCV strains (BK, Hutch and HCV-1). Neither quantity of HCV RNA nor strain type correlated with abnormal transaminases post-transplant. As yet, there has not been an effect of anti-HCV status on actuarial patient and graft survival. This study suggests that anti-HCV is not a contraindication to renal transplantation; however, we would recommend that the pre-transplant evaluation of the anti-HCV positive patient include a liver biopsy to properly stage the disease. Close post-transplant follow-up is required in view of the increased risk for infection and rejection.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0085-2538
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
45
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
238-44
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7510350-Adult,
pubmed-meshheading:7510350-Base Sequence,
pubmed-meshheading:7510350-Female,
pubmed-meshheading:7510350-Hepacivirus,
pubmed-meshheading:7510350-Hepatitis Antibodies,
pubmed-meshheading:7510350-Hepatitis C,
pubmed-meshheading:7510350-Hepatitis C Antibodies,
pubmed-meshheading:7510350-Humans,
pubmed-meshheading:7510350-Immunoblotting,
pubmed-meshheading:7510350-Kidney Transplantation,
pubmed-meshheading:7510350-Liver Diseases,
pubmed-meshheading:7510350-Male,
pubmed-meshheading:7510350-Middle Aged,
pubmed-meshheading:7510350-Molecular Probes,
pubmed-meshheading:7510350-Molecular Sequence Data,
pubmed-meshheading:7510350-Polymerase Chain Reaction,
pubmed-meshheading:7510350-Postoperative Complications,
pubmed-meshheading:7510350-Transplantation, Homologous
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
The impact of hepatitis C virus infection on renal allograft recipients.
|
| pubmed:affiliation |
Department of Medicine, Miami Veterans Administration Hospital, Florida.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|